Category Archives: News from Other Sources

A phase 1 clinical trial has begun in Turin, Italy, to test the safety of RG2833 in adults with Friedreich’s ataxia.

Research studies in mice using two markedly different strategies both resulted in increased life span.

Investigators have safely injected gamma-sarcoglycan genes into an arm muscle in nine people with limb-girdle muscular dystrophy type 2C; high-dose recipients produced gamma-sarcoglycan protein.

An interview with MDA research grantee Matthew Disney explores his group’s findings about small molecules as a potential treatment for myotonic dystrophy.

The latest advances in diagnosis, medical management and the status of therapy development for neuromuscular diseases were covered at MDA’s 2012 Clinical Conferenc.

Researchers are studying the ‘natural history’ of centronuclear/myotubular myopathies and central core disease, with an eye to future trials.

West Virginia University Healthcare has now been designated as an MDA/ALS center by the Muscular Dystrophy Association, in recognition of the high standards of care provided by the team of specialized physicians and therapists for people in West Virgin…

MDA has awarded $300,000 to the Center for Genetic Medicine Research at Children’s National Medical Center to maintain a valuable research mouse testing facility.

The Muscular Dystrophy Association announced today that it has extended its strategic research partnership with the nonprofit biotech ALS Therapy Development Institute (ALS TDI) through 2012, with a $2 million grant.

As progress continues in drug discovery and development at the ALS Therapy Development Institute, MDA’s Augie’s Quest provides $2 million more in support.